UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank…

Cohort studyClinical pharmacology and therapeutics· Aug 2026

UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic Cohort Study.

Reinhold Kreutz, Pimrapat Gebert, Jingwen Luo … Antonios Douros

CardiologyCohort studyQ1IF 4.7

Uromodulin genotype not associated with worsening heart failure risk in patients on loop diuretics.

UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic Cohort Study.

Reinhold Kreutz … Antonios Douros

Clinical pharmacology and therapeutics · Aug 2026

Background

Uromodulin (uromodulin) regulates tubular sodium handling and modulates NKCC2, the molecular target of loop diuretics (loop diuretics).

Methods

Were followed in an intention-to-treat fashion for up to 12 months.

n = 1,426 HF patients

Results

genotype made no difference to heart failure risk

HR 0.95 (95% CI 0.76 to 1.20)

CI crosses the null - not significant

More results

We assessed whether the uromodulin rs13333226 genotype is associated with clinical outcomes among patients with heart failure who initiated loop diuretics.

Cox models estimated confounder-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) comparing rs13333226-AA versus rs13333226-AG/GG genotypes.

More results

Sensitivity analyses restricted follow-up to 3 and 6 months.

In heart failure patients initiating loop diuretics, uromodulin rs13333226 was not associated with effectiveness or safety outcomes.

“

Conclusion

These findings do not support a clinically meaningful pharmacogenetic role for this variant.

UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic Cohort Study.

UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic Cohort Study.

Related papers